Lyra Therapeutics (LYRA) Return on Sales (2021 - 2025)
Historic Return on Sales for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to 239.36%.
- Lyra Therapeutics' Return on Sales fell 1784700.0% to 239.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 35.28%, marking a year-over-year increase of 1016300.0%. This contributed to the annual value of 40.23% for FY2023, which is 3300.0% up from last year.
- Lyra Therapeutics' Return on Sales amounted to 239.36% in Q3 2025, which was down 1784700.0% from 40.64% recorded in Q2 2025.
- In the past 5 years, Lyra Therapeutics' Return on Sales registered a high of 8.29% during Q4 2024, and its lowest value of 1292.91% during Q4 2022.
- Moreover, its 5-year median value for Return on Sales was 42.2% (2024), whereas its average is 172.65%.
- Per our database at Business Quant, Lyra Therapeutics' Return on Sales plummeted by -12426600bps in 2022 and then skyrocketed by 11891000bps in 2023.
- Lyra Therapeutics' Return on Sales (Quarter) stood at 50.25% in 2021, then crashed by -2473bps to 1292.91% in 2022, then skyrocketed by 92bps to 103.81% in 2023, then soared by 108bps to 8.29% in 2024, then crashed by -2989bps to 239.36% in 2025.
- Its Return on Sales stands at 239.36% for Q3 2025, versus 40.64% for Q2 2025 and 46.7% for Q1 2025.